Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do.

Our investigational product, “Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System” (“Melphalan/HDS”), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects.

We have the potential to change the lives of people with rare and life threatening cancers of the liver and believe our innovative approach to drug-delivery is set to become a new standard of care. To date over 700 patients have received our treatment in Europe in both the commercial and clinical setting.

Our medical device is CE Marked in Europe since 2012 as CHEMOSAT®. In prior research, our treatment has outperformed best available therapies and there are many exciting and near-term clinical developments. There is potential to expand the number of people we serve for years to come.

Our Mission

To deliver breakthroughs in therapies for the treatment of patients with primary and metastatic cancers to the liver through the use of novel isolation, saturation and filtration to improve clinical outcomes for patients while reducing drug-related side effects.

Our Team

At Delcath Systems we have an exceptional team of individuals, who each bring with them a personal desire to change the world for people with rare and life-threatening liver conditions.

With over 60 years of experience, our executive team combines expertise in oncological patient care, product commercialization, global operations, finance and investment strategy development and execution.

Dr. Jennifer Simpson, Ph.D.

Chief Executive Officer

Barbra Keck

Chief Financial Officer

John Purpura

Executive Vice President, Global Head of Operations